Cinacalcet - CAS 226256-56-0
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Cinacalcet is the first calcimimetic drug approved by the United States Food and Drug Administration for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
Publictions citing BOC Sciences Products
  • >> More
Sensipar, (R)-N-[-1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine
1.Effects of cinacalcet treatment on QT interval in hemodialysis patients.
Temiz G1, Yalçın AU2, Mutluay R3, Bozacı İ2, Bal C4. Anatol J Cardiol. 2015 Nov 25. doi: 10.5152/AnatolJCardiol.2015.6284. [Epub ahead of print]
OBJECTIVE: Cinacalcet is a calcimimetic drug that acts via calcium-sensing receptors (CaSRs) and increases the sensitivity of CaSRs on the parathyroid gland; thus, it lowers calcium and phosphorus levels as well as parathormone levels. Prolongation of the QT interval is recognized as a risk factor for the development of ventricular arrhythmias and sudden death. Patients with end-stage renal disease (ESRD) are sensitive for QT prolongation and torsade de pointes more than the normal population. In this study, we aimed to evaluate the effects of cinacalcet on the electrocardiogram (ECG), particularly changes in the QT interval, in patients with ESRD.
2.PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism.
Akizawa T1, Kurita N2,3,4,5, Mizobuchi M1, Fukagawa M6, Onishi Y4, Yamaguchi T4,7, Ellis AR8, Fukuma S4,5,9, Alan Brookhart M8,10, Hasegawa T2,3,4,11, Kurokawa K12, Fukuhara S3,5. Sci Rep. 2016 Apr 13;6:19612. doi: 10.1038/srep19612.
Cinacalcet lowers parathyroid hormone levels. Whether it can prolong survival of people with chronic kidney disease (CKD) complicated by secondary hyperparathyroidism (SHPT) remains controversial, in part because a recent randomized trial excluded patients with iPTH <300 pg/ml. We examined cinacalcet's effects at different iPTH levels. This was a prospective case-cohort and cohort study involving 8229 patients with CKD stage 5D requiring maintenance hemodialysis who had SHPT. We studied relationships between cinacalcet initiation and important clinical outcomes. To avoid confounding by treatment selection, we used marginal structural models, adjusting for time-dependent confounders. Over a mean of 33 months, cinacalcet was more effective in patients with more severe SHPT. In patients with iPTH ≥500 pg/ml, the reduction in the risk of death from any cause was about 50% (Incidence Rate Ratio [IRR] = 0.49; 95% Confidence Interval [95% CI]: 0.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related CaSR Products

CAS 135459-87-9 Strontium Ranelate

Strontium Ranelate
(CAS: 135459-87-9)

Strontium ranelate is a dual action bone agent (DABA). It inhibits bone resorption and stimulates bone formation, inhibiting osteoclast differentiation while ac...

CAS 226256-56-0 Cinacalcet

(CAS: 226256-56-0)

Cinacalcet is the first calcimimetic drug approved by the United States Food and Drug Administration for the treatment of secondary hyperparathyroidism in patie...

(CAS: 870964-67-3)

Evocalcet is a calcium-sensing receptor agonist under the development of Kyowa Hakko Kirin. Phase III clinical trials for Secondary hyperparathyroidism are on-g...

CAS 753449-67-1 Ronacaleret

(CAS: 753449-67-1)

Ronacaleret is a calcium-sensing receptor (CaSR) antagonist under the development of GlaxoSmithKline. It is potential for therapeutic utility in the stimulation...

CAS 284035-33-2 NPS-2143

(CAS: 284035-33-2)

NPS-2143(SB 262470A ) is a selective potent calcium ion-sensing receptor antagonist with IC50 of 43 and 41 nM for cytoplasmic Ca2+ concentrations and parathyroi...

CAS 787583-71-5 Encaleret

(CAS: 787583-71-5)

Encaleret is a calcium-sensing receptor (CaSR) antagonist. But in Oct 2011, Phase-II for Osteoporosis in USA was discontinued.

(CAS: 1214922-52-7)

This active molecular is an CaSR (calcium-sensing receptor antagonist) under the developmet of Tobacco and Merck & Co. Calcium-sensing receptor is a member of t...

CAS 478963-79-0 Calcium-Sensing Receptor Antagonists I

Calcium-Sensing Receptor Antagonists I
(CAS: 478963-79-0)

Calcium-Sensing Receptor Antagonists I is an antagonist of calcium-sensing parathyroid hormone receptors.

CAS 324523-20-8 NPS-2143 hydrochloride

NPS-2143 hydrochloride
(CAS: 324523-20-8)

NPS-2143 (SB-262,470A) is a calcilytic drug which acts as an antagonist at the Calcium-sensing receptor (CaSR), and consequently stimulates release of parathyro...

CAS 364782-34-3 Cinacalcet hydrochloride

Cinacalcet hydrochloride
(CAS: 364782-34-3)

Cinacalcet HCl represents a new class of compounds for the treatment of hyperparathyroidism.

Etelcalcetide hydrochloride
(CAS: 1334237-71-6)

Etelcalcetide is a Calcium-sensing receptor agonist as a D-amino peptide calcimimetic for the treatment of secondary hyperparathyroidism. It can bind to and act...

Chemical Structure

CAS 226256-56-0 Cinacalcet

Quick Inquiry

Verification code

Featured Items